The Driving Force Behind New Drug Discovery。




Daiichi Sankyo RD Novare, a technology-led company
that is the driving force behind new drug discoveries.
As a new challenge, we launched the Clinical Research
Laboratory, which accelerates oncology R&D.

President and
Representative Director

徳井 太郎


The strong desire of Daiichi Sankyo RD Novare employees is to create drugs that really work for each patient, and to make as many patients as possible smile with our technology.

To this end, we have begun to take on the challenge of transforming our drug discovery process.

The application of knowledge and technology developed in nonclinical research to the analysis of clinical specimens will provide an accurate understanding of the mechanisms of disease occurring in humans and lead to drug discovery.

In the future, we aim to become a leading player in the drug discovery ecosystem by analyzing clinical samples of cancer in partnership with multiple clinical institutions.


Creating cutting-edge facilities and organizations to ensure reliability.

The clinical research laboratory began full-scale operations in April 2019.
We invested state-of-the-art technology and equipment to
ensure the reliability of data and information through GCP-
compliant organizational operations.

Translational Research Department
Vice President

長澤 康男


The main pillar of the clinical research lab is genomics.
By conducting research in collaboration with informatics, molecular pathology, and genetic analysis, we are able to achieve multi-layered and highly precise analysis.

We are also focusing on building sophisticated IT systems that guarantee security and creating a system for GCP compliance.

We believe that we can ensure the reliability of our clinical research laboratories only by properly processing complexity and vast amounts of human genome information and handling it safely in accordance with the Personal Information Protection Law.


Our specialists who take on the challenge of understanding diseases

Molecular pathology

Analysis of what is happening in the disease lesion site

Translational Research Department
Molecular Pathology Group
Senior Researcher

小林 真季


We aim to conduct highly precise clinical research in molecular pathology by properly handling clinical samples based on histopathological knowledge of the disease, and by identifying disease areas.

By visualizing changes in the expression and localization of the target molecules, we analyze what is occurring at the site of the disease.

Genetic analysis

Analysis of gene expression and genetic mutations
in collaboration with molecular pathology

Translational Research Department
Genomics Group

大島 慶子


In genetic analysis, we analyze genetic expression and mutation in collaboration with molecular pathology.

For example, we deepen our understanding of the effects and side effects of drugs by analyzing cancer tissues and the microenvironment surrounding the cancer tissues, and by performing correlative analyses between histopathology and gene expression.

Translational Research Department
Bioinformatics Group
Senior Director

岡本 敦之


Genomic analysis of clinical samples is also the ultimate analysis of personal information.
Therefore, we have built a rigorous and robust system to properly manage sample tracking and data.


Towards genomic analysis to understand and
hypothesis disease mechanism

Translational Research Department
Genomics Group
Senior Director

和田 直也


We are now working to properly process samples on the
basis of such a robust and secure analytical environment,
and to use our diverse genomics analysis methods and
advanced informatics technologies to understand diseases
at the genome and even epigenome levels.

By pooling the collective power of its staff, Daiichi Sankyo RD Novare is taking on the challenge of fully understanding diseases.
A world in which we can rapidly deliver optimal drugs to each and every patient in need of a new drug.

Clinical Research Laboratories, Accelerating Oncology R&D

With a vision of leading clinical research in the oncology
field in Japan, we took a major step forward in the clinical
research lab of Daiichi Sankyo RD Novare.
The ultimate ideal is the realization of
a world that quickly delivers optimal drugs
to each patient waiting for new drugs.

The Driving Force Behind New Drug Discovery
Internet Explolerには対応しておりません。
Google chrome等モダンブラウザをご利用ください。